Skip to main content
SLAS2024 Main banner
Sartorius Ad
Back

Arijit Chakravarty, PhD, MSc (he/him/his)

Fractal Therapeutics Inc, Massachusetts, United States

Arijit Chakravarty, PhD., CEO of Fractal Therapeutics

I lead a team of cross-disciplinary experts who provide integrated development support to drug discovery and development programs using model-based techniques. We engage with companies to help them design their preclinical and clinical studies, model the data from these studies, and provide real-world answers that can drive their drug R&D programs forward. Over the past seven years, we've worked with close to twenty clients, in some cases starting in lead optimization and staying on all the way to the end of Phase I. I have two decades of experience in the biopharmaceutical industry, spanning multiple therapeutic areas and stages of drug R&D. Before founding Fractal Therapeutics, I spent twelve years in Takeda Pharmaceuticals in various roles of increasing responsibility, leading teams of “wet bench” biologists, pharmacologists and mathematical modelers. I have contributed to ~65 drug development programs, served as a discovery Project Team Leader for seven preclinical and early-clinical programs, and played a pivotal role in over a dozen IND filings. I've co-authored over fifty publications/patents and close to a hundred posters at major meetings, and presented well over a hundred talks at conferences and seminars.

During the ongoing COVID-19 pandemic, as a side project, my collaborators and I have published over twenty peer-reviewed papers on SARS-CoV-2 viral evolution and epidemiology, focusing on the public health implications. In 2021, for example, we predicted that the virus would rapidly evolve to evade neutralizing antibodies, that a vaccine-only strategy would lead to repeated waves of disease and variant-driven rebounds, and that long-term intrahost evolution represented a public-health threat. We continue to work on the issue, making ongoing predictions about the future trajectory of the current crisis, and suggesting practical ways that the issue can be dealt with (rather than ignored) by public health authorities worldwide.

Disclosure information not submitted.

Presentation(s):